|
You are subscribed to Oncology (Cancer) / Hematologic Malignancies. This information has recently been updated, and is now available.
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia
On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
|
This email was sent to Esdek@podam.pl using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·
10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA |
 |
|
|
